FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

26 Mar 20264 min read0 views

GIST

The U.S. Food and Drug Administration today approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe Leukocyte Adhesion Deficiency Type I (LAD-I).

Clinical Editorial

Summary

FDA News Releases published a clinical update in Research Highlights on 26 Mar 2026. The item focuses on FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I. Open the detail page to review the full original feed content.